Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
22 participants
INTERVENTIONAL
2015-11-30
2018-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary outcomes are:
1. \- To compare the additive analgesic efficacy of prior administration of magnesium sulfate to that of placebo and ketamine only, on the effectiveness of intravenous ketamine treatment,
2. \- To study the evolution time of pain and analgesia after the intravenous administration of ketamine and placebo,
3. \- To study the correlation of the analgesic response to administered products respectively ketamine, ketamine and magnesium sulfate, placebo.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Single-center clinical trial, controlled, randomized, double-blind, crossover design, against inactive placebo.
Each patient will receive successively the 3 products (ketamine / placebo, ketamine / magnesium sulfate, placebo / placebo) follows a predeter randomization list, with a wash-out period between each administration.
Visit 1
-Inclusion visit, signature of informed consent form, clinical examination and fill questionnaires.
For women of childbearing age a pregnancy test will be performed.The pain will be measured by a numerical scale.
The pain will be evaluated by scoring on a numerical scale. A booklet for monitoring analgesic concomitant medication and overall pain on a numerical scale will be given to the patient 14 days before the programmed infusion.
Visit 2 : Period 1 Day 0
Clinical examination, return of booklet completed by patient and fill questionnaires.
The pain will be evaluated by scoring on a numerical scale before and after the infusion.
For women of childbearing age a pregnancy test will be performed. Treatment allocation period follows a predeter randomization list. At the end of the infusion, a booklet for monitoring will be given to patients for the following weeks in order to score their overall pain until the next study period.
The output of the hospital patient (CPC / CETD) after each treatment will be authorized by the investigator.
Wash-out period: 5 weeks.
Phone call 1 (Day 1):
Patients will be called by phone to collect adverse events and concomitant medications. If necessary, the patients should return to consult the CPC / CETD for a clinical examination.
Patients will be called the week before their scheduled visit, if at that time their spontaneous pain is still low, according to the opinion of the investigator, the infusion visit will be shifted to allow the pain level back its basal level.
Visit 3 : Period 2 : Day 36 +/- 3 days
Same of period 1.
Phone call 2 J 37 +/- 3 days:
Same of phone call 1.
Visit 4 : Period 3 : Day 72 +/- 3 days
Same of period 1
Phone call 3 J 73 +/- 3 days:
Same of phone call 1.
Visit 5 : Day 108 +/- 3 days
Clinical examination, return of booklet completed by patient and fill questionnaires.
The pain will be evaluated by scoring on a numerical scale For women of childbearing age a pregnancy test will be performed. This visit is the end of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
INTRAVENOUS KETAMINE
Ketamine
Magnesium Sulfate
placebo : sodium chloride
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketamine
Magnesium Sulfate
placebo : sodium chloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient (s) who had never received ketamine infusion under the care of their neuropathic pain;
* History of illness compatible with an injury or disease of the somatosensory system;
* Localized pain in an anatomical neuro territory;
* Neurological examination shows sensory abnormalities,
* The patients of childbearing potential must use effective contraception throughout the study;
* For womens of childbearing age, they will be enrolled in the study after a negative urine pregnancy test; in case of suspicion of pregnancy, a blood pregnancy test should be performed;
* Cooperation and willing to follow the study;
* Acceptance to give written consent;
* Affiliated to the French social security;
* Inscription or acceptation of inscription in the national register of volunteers involved in trials.
Exclusion Criteria
* Patients with one or many contraindication to ketamine administration: known hypersensitivity to ketamine in which one of the constituents of the product, uncontrolled high blood pressure, severe cardiac insufficiency;
* Patients with one or many contraindication of magnesium sulfate administration: Patients with severe renal impairment;
* Patients with one or many contraindication to administration of sodium chloride: water inflation, fluid retention;
* Patients with a medical history and / or surgical judged by the investigator to be not consistent with the clinical trial;
* Patients with drug treatments judged by the investigator to be not consistent with the clinical trial;
* Pregnancy or lactation women;
* Patient who participated in another clinical trial, located in exclusion period or received benefits \> 4500 euros during 12 months before the beginning of trial;
* Patients with cooperation and understanding not to adhere strictly to the conditions provided in the clinical trial;
* Patients receiving a measure of legal protection (guardianship…);
* Patients are not affiliated to the System of the French Social Security
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gisèle PICKERING
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Patrick LACARIN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHU-0235
Identifier Type: -
Identifier Source: org_study_id